AnaptysBio (ANAB) shares were down almost 22% in recent Wednesday trading after Eli Lilly (LLY) said it is removing arthritis drug peresolimab from its pipeline.
AnaptysBio is developing rosnilimab, an arthritis treatment that is similar to peresolimab, according to media reports.
AnaptysBio previously said on Aug. 5 in its Q2 earnings release that top-line results are expected in Q1 2025 for a phase 2b trial to treat rheumatoid arthritis with rosnilimab.
Price: 24.17, Change: -6.64, Percent Change: -21.54
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。